Welcome to our dedicated page for Atara Biotherapeutics SEC filings (Ticker: ATRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Atara Biotherapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Atara Biotherapeutics's regulatory disclosures and financial reporting.
Cherry Brian N reported acquisition or exercise transactions in this Form 4 filing.
Atara Biotherapeutics director Brian N. Cherry received a grant of 24,000 shares of common stock on June 11, 2026 as a compensation award. The shares are in the form of restricted stock units that vest in three equal annual installments on the first, second, and third anniversaries of June 11, 2026, subject to his continuous service. Following this grant, Cherry directly holds 62,320 shares of Atara common stock.
Atara Biotherapeutics, Inc. director Brian N. Cherry filed an initial ownership report showing his holdings in the company’s common stock. The filing lists direct ownership of 38,320 shares of Common Stock after the reported holdings, with no specific buy or sell transaction disclosed.
Atara Biotherapeutics, Inc. reported governance updates from its June 2026 shareholder meeting and a new board appointment. The board named Brian Cherry as a Class I director effective June 11, 2026, and appointed him to the Audit Committee. He will receive an initial grant of 24,000 restricted stock units vesting annually over three years, plus an annual cash retainer of $55,000 under the non‑employee director program.
Stockholders elected two directors to terms running until the 2029 annual meeting, approved on an advisory basis the compensation of named executive officers, and approved an amendment to the 2024 Equity Incentive Plan. They also ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
HEIDEN WILLIAM K reported acquisition or exercise transactions in this Form 4 filing.
Atara Biotherapeutics director William K. Heiden received a grant of 12,000 shares of Common Stock in the form of restricted stock units as compensation. The award was recorded at a price of $0.00 per share and is not an open-market purchase.
These restricted stock units will vest on the earlier of June 9, 2027 or the date of the next annual meeting of stockholders, provided he maintains continuous service. Following this grant, Heiden directly holds 34,188 shares of Atara Biotherapeutics common stock.
Fust Matthew K reported acquisition or exercise transactions in this Form 4 filing.
Atara Biotherapeutics director Matthew K. Fust received an equity award of 12,000 shares of common stock in the form of restricted stock units. The award was granted at no cash cost and will vest on the earlier of June 9, 2027 or the next annual stockholder meeting, subject to his continuous service. Following this grant, he holds 30,188 shares directly.
Ciongoli Gregory Austin reported acquisition or exercise transactions in this Form 4 filing.
Atara Biotherapeutics director Gregory A. Ciongoli reported an equity compensation award and updated his indirect holdings. He received a grant of 12,000 shares of common stock as a restricted stock unit award at a price of $0.00 per share.
These restricted stock units vest on the earlier of June 9, 2027 or the date of the next annual meeting of stockholders, subject to his continuous service. The filing also reports 1,209,395 shares of common stock indirectly held by Adiumentum Capital Fund I LP, a Delaware limited partnership with which Ciongoli and its general partner are associated, while all parties disclaim beneficial ownership except to the extent of any pecuniary interest.
Atara Biotherapeutics President and CEO Nguyen AnhCo reported an automatic sale of common stock tied to equity compensation. On May 18, 2026, 5,241 shares of common stock were sold at a weighted average price of $9.1289 per share. According to the disclosure, the shares were sold automatically to satisfy tax withholding obligations triggered by the vesting of previously granted restricted stock units under a sale-to-cover provision, rather than as a discretionary open-market sale for portfolio reasons. Following this transaction, AnhCo directly holds 137,837 shares of Atara common stock.
Atara Biotherapeutics Chief Accounting Officer Yanina Grant-Huerta reported the sale of 2,414 shares of common stock. The shares were sold on May 18, 2026 at a weighted average price of $9.1286 per share, in multiple trades between $9.12 and $9.40.
According to the disclosure, these shares were sold automatically to satisfy tax withholding obligations tied to the vesting of previously granted restricted stock units under a sale-to-cover provision. After the transaction, Grant-Huerta directly holds 49,636 shares of Atara common stock.
ATRA submitted a notice for the settlement/sale of 13,887 shares of Common Stock on 05/15/2026, described as settlement of vested RSUs issued under an S-8 registration plan. The excerpt also shows a prior sale of 2,996 shares on 03/02/2026.
ATRA submitted a Form 144 notice reporting the settlement and disposition of Common Stock tied to employee equity. The filing shows 6,393 shares settled on 05/15/2026 as payment for vested RSUs issued under an S-8 registration, and a prior sale of 2,104 shares on 03/02/2026.